Luciana Martins Rozman

Luciana Martins Rozman

Auto-generated profile, based on publicly available information

Luciana Martins Rozman

Universidade São Judas Tadeu, Brasil

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
LRLuciana Martins Rozman
Luciana Martins Rozman
ACAlessandro Gonçalves Campolina
Alessandro Gonçalves Campolina
RLRossana Verónica Mendonça López
Rossana Verónica Mendonça López
SKSilvia Takanohashi Kobayashi
Silvia Takanohashi Kobayashi
TCToshio Chiba
Toshio Chiba
Patricia SoarezPatricia Soarez
Patricia Soarez
Background: Integrating palliative care into standard oncology care has been recommended for cancer patients. Early palliative care is associated with less aggressive treatment at the end of life. Objective: To describe cancer patients receiving palliative care in Brazil, determining the time from entry into palliative care to death, and investigating whether late referral to palliative care is associated with aggressive end-of-life treatment. Design: This was a cross-sectional study of cancer patients receiving palliative care in Brazil. Setting/Subjects: Subjects were 2985 cancer patients ≥18 years of age who received at least two palliative care visits at the São Paulo State Cancer Institute, in the city of São Paulo, Brazil, and died between 2010 and 2013. Measurements: We evaluated the time from the first palliative care consult to death, stratifying cases by the timing of entry into palliative care (≥3 or <3 months before death). The associations between early palliative care and indicators of aggressive treatment were assessed by Pearson's chi-square test and Fisher's exact test. Results: The overall median time between entry into palliative care and death was 34 days (mean, 72 days) and was significantly shorter in 2013 than in 2010 (p < 0.001). The number of emergency department visits was significantly lower among the patients who entered palliative care earlier (p < 0.001). Conclusions: Among cancer patients in Brazil, late referral to palliative care is common. Patients who enter palliative care earlier appear to receive less aggressive end-of-life treatment.

15 October 2019 in BMJ Supportive & Palliative Care
Verified
Journal Article
Closed access
PDF file
LRLuciana Martins Rozman
Luciana Martins Rozman
ACAlessandro Gonçalves Campolina
Alessandro Gonçalves Campolina
RLRossana Mendoza Lopez
Rossana Mendoza Lopez
TCToshio Chiba
Toshio Chiba
PSPatricia Coelho De Soárez
Patricia Coelho De Soárez
Palliative care (PC) improves the quality of life of patients with diseases such as cancer, and several studies have shown a reduction in costs among patients who use PC services when compared with those receiving standard oncological treatments. Most studies on PC costs are carried out in high-income countries. There is a lack of these types of studies in middle-income and low-income countries and of better evidence about this intervention. Objective To describe resource utilisation and costs among patients with cancer in a Brazilian quaternary hospital by cancer localisation and per month of treatment before death. Methods This study is a description of retrospective costs to estimate the costs of formal healthcare sector associated with PCs, from the perspective of a public quaternary cancer hospital. Unit costs were estimated using microcosting and macrocosting approaches. Setting/Participants Patients older than 18 years old who died from 2010 to 2013 and who had at least two visits in PC and/or made use of hospice care. Results Among the 2985 patients included in the study, the average cost per patient was US$12 335, ranging from US$8269 for patients with pancreatic cancer to US$19 395 for patients with brain cancer. The main costing item was hospital admission (47.6% of the total cost), followed by hospice care (29.5%) and medical and other supplies (11.1%). Conclusions The study clarified the direct medical costs and the profile and use of resources of patients with cancer who need PC, and can help in the planning and allocation of resources in cancer care.

1 May 2007 in Cadernos de Saude Publica
Verified
Journal Article
Open access
PDF file
LRLuciana Martins Rozman
Luciana Martins Rozman
ASAugusto Hasiak Santo
Augusto Hasiak Santo
MRMauro Abrahão Rozman
Mauro Abrahão Rozman
No início dos anos 90, observou-se aumento da resistência do Mycobacterium tuberculosis às drogas antituberculose, com alta prevalência entre pacientes HIV+. Neste estudo, foram avaliados a freqüência de resistência, o perfil de sensibilidade do M. tuberculosis às drogas e os fatores predisponentes à resistência entre indivíduos HIV+ nos municípios de Santos, São Vicente, Cubatão, Praia Grande e Guarujá, Estado de São Paulo, Brasil. Foram pesquisados os prontuários de 301 pacientes com resultado de cultura positivo entre 1993 e 2003. A resistência ocorreu em 57 (18,9%) pacientes com a seguinte distribuição: 32 (10,6%) apresentaram tuberculose multirresistente (resistência ao menos à Rifampicina e Isoniazida); 4 (1,3%) casos apresentaram resistência a duas ou mais drogas e 21 (7%) à monorresistência. Observou-se resistência secundária em 70,2% dos casos. Estatisticamente associadas à tuberculose resistente foram: tratamento anterior com drogas antituberculose, tempo de diagnóstico de HIV e hospitalização prévia. Em análise multivariada, apenas tratamento anterior, ajustado por faixa etária, mostrou-se associado (OR = 5,49; IC95%: 2,60-11,60). A ocorrência de resistência em 18,9% dos casos e multirresistência em aproximadamente 10% confirmam a relevância deste problema entre pacientes HIV+ na Baixada Santista.

10 March 2017 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
ASAna Marli Christovam Sartori
Ana Marli Christovam Sartori
LRLuciana Martins Rozman
Luciana Martins Rozman
TDTassia Cristina Decimoni
Tassia Cristina Decimoni
RLRoseli Leandro
Roseli Leandro
HNHillegonda Maria Dutilh Novaes
Hillegonda Maria Dutilh Novaes
Patricia SoarezPatricia Soarez
Patricia Soarez
Background: In Brazil, since 2005, the Ministry of Health requires Health Economic Evaluation (HEE) of vaccines for introduction into the National Immunization Program. Objectives: To describe and analyze the full HEE on vaccines conducted in Brazil from 1980 to 2013. Methods: Systematic review of the literature. We searched multiple databases. Two researchers independently selected the studies and extracted the data. The methodological quality of individual studies was evaluated using CHEERS items. Results: Twenty studies were reviewed. The most evaluated vaccines were pneumococcal (25%) and HPV (15%). The most used types of HEE were cost-effectiveness analysis (45%) and cost-utility analysis (20%). The research question and compared strategies were stated in all 20 studies and the target population was clear in 95%. Nevertheless, many studies did not inform the perspective of analysis or data sources. Conclusions: HEE of vaccines in Brazil has increased since 2008. However, the studies still have methodological deficiencies.

20 September 2021 in Journal of Palliative Medicine
Verified
Journal Article
Closed access
LRLuciana Martins Rozman
Luciana Martins Rozman
ACAlessandro Gonçalves Campolina
Alessandro Gonçalves Campolina
EPElizabeth González Patiño
Elizabeth González Patiño
PSPatrícia Coelho de Soárez
Patrícia Coelho de Soárez
Background: There have been few studies evaluating the costs of palliative care (PC) in low- and middle-income countries (LMICs), especially for patients with cancer. Objectives: The objective of this study was to identify the sociodemographic and clinical variables that could explain the cost per day of PC for cancer in Brazil. Methods: This was a retrospective cost analysis of PC at a quaternary cancer center in São Paulo, Brazil, between January 2010 and December 2013. Factors influencing the cost per day were assessed with generalized linear models and generalized linear-mixed models in which the random effect was the site of the cancer. Results: The study included 2985 patients. The mean total cost per patient was $12,335 (standard deviation [SD] = 14,602; 95% confidence interval [CI] = 11,803 to 12,851). The mean cost per day per patient was $325.50 (SD = 246.30, 95% CI = 316.60 to 334.30). There were statistically significant differences among cancer sites in terms of the mean cost per day. Multivariate analysis revealed that the drivers of cost per day were Karnofsky performance status, the number of hospital admissions, referral to PC, and place of death. Place of death had the greatest impact on the cost per day; death in a hospital and in hospice care increased the mean cost per day by $1.56 and $1.83, respectively. Conclusion: To allocate resources effectively, PC centers in LMICs should emphasize early enrollment of patients at PC outpatient clinics, to avoid hospital readmission, as well as advance planning of the place of death.

16 January 2023 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
FMFernando Henrique de Albuquerque Maia
Fernando Henrique de Albuquerque Maia
LRLuciana Martins Rozman
Luciana Martins Rozman
HCHeloísa de Andrade Carvalho
Heloísa de Andrade Carvalho
Patricia SoarezPatricia Soarez
Patricia Soarez
Background: Stereotactic ablative radiotherapy (SABR) is recommended as first-choice treatment to inoperable early-stage non-small cell lung cancer (NSCLC). However, it is not widely adopted in developing countries, and its cost-effectiveness is unclear. We aimed to perform a systematic review of full economic evaluations (EE) that compared SABR with other radiotherapy or surgical procedures to assess the results and methodological approach. Methods: The protocol was registered on PROSPERO (CRD42021241640). We included full EE studies with early-stage NSCLC in which one group was submitted to SABR. Studies that were partial EE, included advanced NSCLC or other neoplasm were excluded. We performed the last search on June 2021 in Medline, EMBASE and other databases. The reporting quality were assessed by CHEERS checklist. The main characteristics of each study were tabulated, and the results were presented by a narrative synthesis. Results: We included nine studies. Three compared radiotherapy techniques, in which SABR was found to be dominant or cost-effective. Six compared SABR with surgery, and in this group, there was not a unanimous decision. All included only direct healthcare costs but varied about categories included. The parameters used in the model-based studies were highly heterogeneous using mixed data from various sources. The items properly reported varied from 29 to 67%. Conclusions: The studies were all from developed countries and lacked in reporting quality. We recommend that developing countries produce their own studies. More strict alignment to reporting guidelines and use of robust evidence as model parameters are also advised.